Class Action Lawsuit Targets REGENXBIO Over RGX-111 Gene Therapy Disclosures

Law firm Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against REGENXBIO Inc. ($REGENXBIO), alleging that the gene therapy developer made materially false and misleading statements regarding its RGX-111 development program and associated clinical trial results. The litigation covers a significant window spanning nearly four years, affecting investors who purchased company securities between February 9, 2022 and January 27, 2026, with a lead plaintiff deadline set for April 14, 2026.

Key Details of the Litigation

The class action complaint centers on alleged misrepresentations and omissions related to REGENXBIO's RGX-111 gene therapy development efforts. RGX-111 represents a critical asset in the company's pipeline, targeting inherited retinal disease, and the alleged discrepancies concerning its clinical trial results have triggered investor action.

Key aspects of the lawsuit include:

• Covered period: February 9, 2022 through January 27, 2026 (nearly four years)
• Securities included: All REGENXBIO Inc. securities purchased during this window
• Lead plaintiff deadline: April 14, 2026
• Core allegations: Materially false and misleading statements regarding RGX-111 development and clinical trial data
• Plaintiff counsel: Bronstein, Gewirtz & Grossman LLC, a firm specializing in securities litigation

The extended timeline of the alleged misconduct—from early 2022 through early 2026—suggests potential widespread disclosure failures spanning multiple reporting periods and investor communications. This extended window indicates the complaint covers a period when the company may have provided guidance, quarterly earnings updates, and clinical trial disclosures that plaintiffs contend contained material misstatements.

Market Context: Gene Therapy Sector Under Scrutiny

The lawsuit against REGENXBIO reflects broader investor scrutiny within the gene therapy sector, a space that has experienced significant volatility following clinical setbacks and regulatory challenges across multiple companies.

REGENXBIO operates in the increasingly competitive gene therapy landscape, where AAV-based therapies—the company's core technology platform—have faced both significant promise and notable setbacks. The gene therapy sector has been particularly sensitive to clinical trial data and regulatory outcomes, as companies depend heavily on successful proof-of-concept demonstrations to justify valuations and attract investor capital.

Key market context factors:

• Gene therapy volatility: The sector has experienced sharp stock price movements tied to clinical trial announcements
• Regulatory intensity: FDA scrutiny of gene therapy programs has increased, particularly regarding manufacturing, quality, and long-term safety data
• Disclosure standards: Investors increasingly demand granular, real-time disclosure of clinical development progress
• Investor activism: Securities litigation against biotech companies has risen as institutional investors demand accountability for clinical representations

The RGX-111 program represents a significant value driver for REGENXBIO, making the accuracy of clinical trial communications essential to investor decision-making. Any material misstatements about program progress, efficacy data, or trial outcomes could have influenced investment decisions and stock valuation during the covered period.

Investor Implications: Capital Preservation and Corporate Governance

For REGENXBIO shareholders, this litigation presents several critical considerations:

Valuation Impact: Securities lawsuits can affect company stock price through multiple mechanisms, including negative publicity, settlement costs, and reduced investor confidence in management's credibility and disclosure controls.

Settlement Exposure: While early-stage litigation, potential settlement obligations could require material cash outflows or equity issuance, diluting existing shareholders. Defense costs will also accumulate throughout the litigation process.

Clinical Development Timeline: The allegations specifically targeting RGX-111 disclosures may prompt heightened regulatory and investor scrutiny of ongoing clinical work, potentially affecting the company's ability to execute its development strategy without additional public skepticism.

Insurance and Indemnification: REGENXBIO likely maintains directors and officers (D&O) liability insurance that could cover portions of settlement obligations and defense costs, though policy limits and coverage disputes may arise.

Disclosure Controls: The lawsuit underscores the importance of robust disclosure controls, particularly in biotech where clinical data interpretation and communication significantly influence investor perception. Management and board oversight of disclosure practices will likely face increased scrutiny.

For the broader biotech investment community, the litigation reinforces that gene therapy companies must maintain exceptionally rigorous disclosure standards around clinical program progress. Investors evaluating other gene therapy developers should examine the quality and timeliness of clinical data communications, management credibility track records, and disclosure control mechanisms.

Looking Forward

As the April 14, 2026 lead plaintiff deadline approaches, the case will enter a critical phase. Interested investors who purchased REGENXBIO securities during the covered period should carefully review the complaint details and consult with legal counsel regarding eligibility and claim procedures.

The outcome of this litigation will likely influence how REGENXBIO manages future disclosures and may establish important precedent regarding disclosure obligations for gene therapy developers. For the company, demonstrating robust internal controls and transparent communications going forward will be essential to rebuilding investor confidence and defending against potential damages in this action.

REGENXBIO shareholders should monitor case developments closely, including any settlement announcements or adverse rulings, as these could materially impact the company's financial position and stock performance.